Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

Vincenza Conteduca, Salvatore Luca Burgio, Cecilia Menna, Elisa Carretta, Lorena Rossi, Emanuela Bianchi, Carla Masini, Dino Amadori, Ugo De Giorgi

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND In this retrospective study, we assessed chromogranin A (CgA) baseline value as a possible factor associated with poor prognosis in metastatic castration-resistant prostate cancer (CRPC). METHODS Thirty-five patients with metastatic CRPC progressing after docetaxel chemotherapy treated with enzalutamide are subdivided into three groups: serum CgA level was normal when

Original languageEnglish
Pages (from-to)1691-1696
Number of pages6
JournalProstate
Volume74
Issue number16
DOIs
Publication statusPublished - Dec 1 2014

Keywords

  • castration-resistant prostate cancer
  • chromogranin A
  • enzalutamide
  • outcome
  • PSA

ASJC Scopus subject areas

  • Urology
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide'. Together they form a unique fingerprint.

Cite this